The elaborate advances towards the blueprinting of the altered molecular networks that lie behind cancer development have paved the way for targeted therapy in cancer. There are currently more than 400 antibody based drugs in development for the treatment of cancer. What and where they are targeting has to date only been a fragmented knowledge. First in place, BioSeeker has surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical development to established therapy leaders in the market place. Drug targets and their associated antibodies have been analyzed by BioSeeker according to:
34 Different molecular functions of target
13 Major signaling pathways
Cancer stem cells
Conjugated antibodies
Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase Inhibition
31 Targeted cancer indications
Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures
Antibody therapeutic companies
Single target analysis of the 132 antibody targets is performed, including targeted cancer indications, antibody drugs involved and their developmental stages. In total more than 420 clinical trials are included in this analysis, covering more than 30 different cancer indications plus diagnosis and supportive care.
This report serves as a serious reference for professionals interested in the development of oncology drug targets and selection/validation of targeting strategies.
